Inverted follicular keratosis (IFK) is a rare benign neoplasm of the follicular infundibulum and typically presents as a solitary, nonpigmented verrucous papule on the head and neck of older males and can mimic viral warts, basal cell carcinoma (BCC), or squamous cell carcinoma (SCC). To the best of our knowledge, this represents the first reported association between repretinib treatment and benign keratoses with IFK-like features. Further studies are needed to clarify the clinical significance and biological implications of this observation.

P1, N=64, Not yet recruiting, Blau Farmaceutica S.A.

P=N/A, N=418, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Mar 2025

Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS trial. Luspatercept represents an effective treatment option in various mutational backgrounds in LR MDS. Trial Registration: ClinicalTrials.gov Identifier: NCT03682536.

P3, N=100, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.

P2, N=60, Recruiting, Yale University | Not yet recruiting --> Recruiting

P1, N=68, Completed, Longbio Pharma | Active, not recruiting --> Completed

P2, N=120, Recruiting, University of Washington | Trial completion date: Dec 2027 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Oct 2026

P3, N=0, Withdrawn, Akebia Therapeutics | N=71 --> 0 | Suspended --> Withdrawn

P3, N=0, Withdrawn, Akebia Therapeutics | N=71 --> 0 | Suspended --> Withdrawn

P4, N=40, Active, not recruiting, Gangnam Severance Hospital | N=77 --> 40

Mice lacking EPOR from mature oligodendrocytes show subtle deficiencies of adult myelination in hippocampal fimbria and mild working memory deficits. These gain- and loss-of-function experiments may further suggest EPO as clinically safe treatment for remyelination therapies.